The global PCM market was worth $26bn in 2007 and is expected to grow at a CAGR of 11.4% to reach $40bn by 2011. Contract manufacturing in India and China is forecast to expand at a CAGR of 20% through to 2011. Big Pharma are increasingly outsourcing manufacturing to low cost destinations due to cost and margin pressures, and India and China offer skilled manpower and a robust manufacturing infrastructure.

New GMP standard, manufacturing facility project, pharmaceutical synthesis process, QA/QS, packaging, automation, PAT, Part 11, pharmaceutical water system, API & CMO and other innovative technologies will be discussed in this event.

Furthermore, we would bring you some proactive thoughts on how to screen out qualified local partners? Any update regulations by state? What are the advantages in manufacturing China? Where is the best location for your plant? Beijing, Tianjin or Shanghai?

2010 Highlights & Networking:

 - Strategical topics for the local and oversea pharmaceutical manufacturing giants.

 - Global manufacturer - outsourcing concern and criteria?

 - Supporting the sustainable Implementation of operational excellence.

 - Local manufacturer's 3- 5 years capacity strategy - how to moving up the value chain?

 - China latest drug reform, new GMP standard and technology transfer issues.

 - Facilitating and Achieving QbD for drug products.

 - Green manufacturing strategies - Harnessing the opportunities for cost reduction.

 - PAT, process Improvement and cost reduction.

 - Developing a flexible, multi-product manufacturing strategy.

 - Creating the pharmaceutical facility of the future.